Patient Gateway

RSS Feed

Imfinzi plus Imdelltra improves survival in Phase III extensive stage small cell lung cancer trial

Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

Extended-Interval Tarlatamab Dosing Offers Pharmacists More Flexible Administration Windows in SCLC

Promising Results: Pumitamig and Elfe-D in SCLC

Subcutaneous Tarlatamab Safe, Active Against ES-SCLC Tumors in Phase 1B Trial

Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

DeLLphi-305: Durvalumab + Tarlatamab Improves Survival in First-Line ES-SCLC

New Drug Combination Shows Promise Against Lung Cancer